DOP2012000007A - Formulaciones de imiquimod de concentracion de dosificacion inferior y regimenes de dosificacion cortos para tratar verrugas genitales y perianales - Google Patents

Formulaciones de imiquimod de concentracion de dosificacion inferior y regimenes de dosificacion cortos para tratar verrugas genitales y perianales

Info

Publication number
DOP2012000007A
DOP2012000007A DO2012000007A DO2012000007A DOP2012000007A DO P2012000007 A DOP2012000007 A DO P2012000007A DO 2012000007 A DO2012000007 A DO 2012000007A DO 2012000007 A DO2012000007 A DO 2012000007A DO P2012000007 A DOP2012000007 A DO P2012000007A
Authority
DO
Dominican Republic
Prior art keywords
imiquimod
formulations
perianal
dosage
genital
Prior art date
Application number
DO2012000007A
Other languages
English (en)
Inventor
Sharon F Levy
James H Kulp
Kodumudi S Balaji
Jason J Wu
Michael T Nordsiek
James H Lee
Tze-Chiang Meng
Valyn S Bahm
Robert Babilon
Original Assignee
Medicis Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43449661&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2012000007(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medicis Pharmaceutical Corp filed Critical Medicis Pharmaceutical Corp
Publication of DOP2012000007A publication Critical patent/DOP2012000007A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se divulgan y se describen formulaciones farmacéuticas y métodos para el suministro tópico o transdérmico de 1 isobutil 1H-imidazol [4, 5 c] quinolin-4 amina o 1 (2 metilpropil) 1H imidazol[4,5 c]quinolin 4 amina, es decir, imiquimod, para tratar verrugas genitales/perianales con duraciones más cortas de terapia que las prescritas actualmente para la crema de imiquimod al 5% AldaraMR comercialmente disponible, como ahora se aprueba por la U.S. Food & Drug Administration (FDA). Más específicamente, también se divulgan y se describen formulaciones de imiquimod de concentración de dosificación inferior para suministrar una dosis eficaz de imiquimod para tratar verrugas genitales/perianales con un perfil de seguridad aceptable y regímenes de dosificación que son más cortos y más convenientes para el uso del paciente que el régimen de dosificación aprobado actualmente por la U.S. Food & Drug Administration (FDA) para la crema de imiquimod al 5% AldaraMR para tratar verrugas genitales/perianales.
DO2012000007A 2009-07-13 2012-01-11 Formulaciones de imiquimod de concentracion de dosificacion inferior y regimenes de dosificacion cortos para tratar verrugas genitales y perianales DOP2012000007A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22520209P 2009-07-13 2009-07-13
US34147610P 2010-03-30 2010-03-30
US34172110P 2010-04-01 2010-04-01
US12/771,076 US20110207766A1 (en) 2009-07-13 2010-04-30 Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts

Publications (1)

Publication Number Publication Date
DOP2012000007A true DOP2012000007A (es) 2012-09-30

Family

ID=43449661

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2012000007A DOP2012000007A (es) 2009-07-13 2012-01-11 Formulaciones de imiquimod de concentracion de dosificacion inferior y regimenes de dosificacion cortos para tratar verrugas genitales y perianales

Country Status (19)

Country Link
US (10) US20110207766A1 (es)
EP (1) EP2453747B1 (es)
AR (1) AR077747A1 (es)
AU (1) AU2010274097B2 (es)
BR (1) BR112012000797A2 (es)
CL (1) CL2010000524A1 (es)
CR (1) CR20120068A (es)
DO (1) DOP2012000007A (es)
EA (1) EA025993B1 (es)
ES (1) ES2653313T3 (es)
GE (1) GEP20156418B (es)
IL (1) IL217518A0 (es)
MX (1) MX336923B (es)
PE (1) PE20110064A1 (es)
PL (1) PL2453747T3 (es)
TW (1) TWI574689B (es)
UY (1) UY32735A (es)
WO (1) WO2011008324A1 (es)
ZA (1) ZA201301397B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2115140B8 (en) * 2007-01-31 2017-01-25 Chongxi Yu Positively charged water-soluble prodrugs of 1H-imidazo[4,5-c]quinolin-4-amines and related compounds with very high skin penetration rates
DK2378876T3 (en) 2008-12-19 2019-03-11 Medicis Pharmaceutical Corp IMIQUIMOD FORMULATIONS WITH LOWER DOSAGE STRENGTH AND SHORT-TERM DOSAGE PLAN FOR TREATMENT OF ACTINIC KERATOSIS
MX336923B (es) 2009-07-13 2016-02-05 Medicis Pharmaceutical Corp Formulaciones de imiquimod de concentracion de dosificacion inferior y regimenes de dosificacion cortos para tratar verrugas genitales y perianales.
US9072876B2 (en) 2010-08-05 2015-07-07 Medicis Pharmaceutical Corporation Pump systems and methods for storing and dispensing a plurality of precisely measured unit-doses of imiquimod cream
US9372907B2 (en) * 2013-11-26 2016-06-21 Sap Se Table placement in distributed databases
TW201630606A (zh) * 2015-01-21 2016-09-01 諾華公司 包含局部藥物之蓋崙（ｇａｌｅｎｉｃ）調配物
US20190029974A1 (en) * 2015-09-11 2019-01-31 Rxi Pharmaceuticals Corporation Methods for treating skin disorders and conditions utilizing haptens
US20210045458A1 (en) * 2018-01-19 2021-02-18 Luxe Ventures Llc Sexual health garments and methods of using the same

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA677797A (en) 1955-11-18 1964-01-14 Minnesota Mining And Manufacturing Company Sheet material having a pressure-sensitive adhesive coating of acrylate ester copolymer
US4722941A (en) * 1978-06-07 1988-02-02 Kali-Chemie Pharma Gmbh Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof
US4411893A (en) * 1981-08-14 1983-10-25 Minnesota Mining And Manufacturing Company Topical medicament preparations
IL73534A (en) * 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US4751087A (en) 1985-04-19 1988-06-14 Riker Laboratories, Inc. Transdermal nitroglycerin delivery system
US4746515A (en) * 1987-02-26 1988-05-24 Alza Corporation Skin permeation enhancer compositions using glycerol monolaurate
US5238944A (en) * 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US5736553A (en) * 1988-12-15 1998-04-07 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo 4,5-C!quinolin-4-amine
US4929624A (en) * 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
US5268376A (en) * 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
SE9601528D0 (sv) 1996-04-23 1996-04-23 Pharmacia Ab Transdermally administered dextromethorphan as antitissue agent
US6125261A (en) * 1997-06-02 2000-09-26 Hughes Electronics Corporation Method and system for communicating high rate data in a satellite-based communications network
UA67760C2 (uk) 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
US20030007939A1 (en) * 1998-07-31 2003-01-09 Howard Murad Pharmaceutical compositions and methods for managing dermatological conditions
US6486168B1 (en) 1999-01-08 2002-11-26 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
US20020058674A1 (en) * 1999-01-08 2002-05-16 Hedenstrom John C. Systems and methods for treating a mucosal surface
CN1555264A (zh) * 1999-01-08 2004-12-15 3M 用于治疗粘膜病症的含咪喹莫特或其它免疫应答调节剂的制剂
US20030072814A1 (en) * 1999-12-16 2003-04-17 Maibach Howard I. Topical pharmaceutical composition for the treatment of warts
US6894060B2 (en) 2000-03-30 2005-05-17 3M Innovative Properties Company Method for the treatment of dermal lesions caused by envenomation
US20020055517A1 (en) 2000-09-15 2002-05-09 3M Innovative Properties Company Methods for delaying recurrence of herpes virus symptoms
CA2449754A1 (en) 2001-06-15 2002-12-27 3M Innovative Properties Company Immune response modifiers for the treatment of periodontal disease
WO2003045391A1 (en) 2001-11-29 2003-06-05 3M Innovative Properties Company Pharmaceutical formulations comprising an immune response modifier
US9668972B2 (en) * 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US7893083B2 (en) * 2003-01-06 2011-02-22 Eugene Mandrea Method of treating genital herpes
EP1603476A4 (en) * 2003-03-13 2010-01-13 3M Innovative Properties Co PROCESS FOR REMOVING TATTOO
NZ567227A (en) * 2003-03-13 2010-01-29 3M Innovative Properties Co Methods of improving skin quality through topical application of an immune response modifier such as imiquimod
US7699057B2 (en) * 2003-03-13 2010-04-20 3M Innovative Properties Company Methods for treating skin lesions
US20040192585A1 (en) * 2003-03-25 2004-09-30 3M Innovative Properties Company Treatment for basal cell carcinoma
US20040265351A1 (en) 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
US7521459B2 (en) * 2003-07-28 2009-04-21 Metabeauty Inc. Method for treating damaged skin
US20090232755A1 (en) * 2003-07-28 2009-09-17 Leslie Baumann Combination therapies for treating photodamaged skin
CA2536249A1 (en) * 2003-08-25 2005-03-10 3M Innovative Properties Company Delivery of immune response modifier compounds
JP2007504145A (ja) * 2003-08-25 2007-03-01 スリーエム イノベイティブ プロパティズ カンパニー 免疫刺激性の組み合わせおよび治療
US20060216333A1 (en) * 2003-09-02 2006-09-28 Miller Richard L Methods related to the treatment of mucosal associated conditions
CA2537763A1 (en) * 2003-09-05 2005-03-17 3M Innovative Properties Company Treatment for cd5+ b cell lymphoma
GB0321615D0 (en) * 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
CN1922137A (zh) * 2003-12-31 2007-02-28 太景生物科技股份有限公司 蛋白酶抑制剂
WO2005077411A2 (en) * 2004-02-10 2005-08-25 Innate Pharma Composition and method for the treatment of carcinoma
US20080125485A1 (en) * 2004-02-17 2008-05-29 Action Medicines Use of 2,5-Dihydroxybenzene Derivatives for Treating Actinic Keratosis
WO2005079143A2 (en) * 2004-02-19 2005-09-01 Occell Inc. Topical formulations for the treatment of skin conditions
EP1735010A4 (en) * 2004-04-09 2008-08-27 3M Innovative Properties Co METHODS, COMPOSITIONS AND PREPARATIONS FOR ADMINISTRATION OF IMMUNE RESPONSE MODIFIERS (MRI)
US20070196293A1 (en) * 2004-06-07 2007-08-23 Jie Zhang Compositions and methods for treating photo damaged skin
US20070190124A1 (en) * 2004-06-07 2007-08-16 Jie Zhang Two or more solidifying agent-containing compositions and methods for dermal delivery of drugs
US20070196323A1 (en) * 2004-06-07 2007-08-23 Jie Zhang Polyvinyl alcohol-containing compositions and methods for dermal delivery of drugs
US20070196452A1 (en) * 2004-06-07 2007-08-23 Jie Zhang Flux-enabling compositions and methods for dermal delivery of drugs
US20070196457A1 (en) * 2004-06-07 2007-08-23 Jie Zhang Two or more volatile solvent-containing compositions and methods for dermal delivery of drugs
US20070196453A1 (en) * 2004-06-07 2007-08-23 Jie Zhang Two or more non-volatile solvent-containing compositions and methods for dermal delivery of drugs
CN1286529C (zh) 2004-06-11 2006-11-29 华中科技大学 具有皮肤靶向性的药物组合物及其制备方法和用途
US20060062755A1 (en) * 2004-09-21 2006-03-23 Woodward John R Method of cancer screening; method of cancer treatment; and method of diabetes treatment
DE102004049223A1 (de) * 2004-10-08 2006-04-20 Johannes-Gutenberg-Universität Mainz Zubereitung zum Impfen, Impfverfahren und Verwendung einer Impf-Zubereitung
US20060105029A1 (en) * 2004-11-12 2006-05-18 Jie Zhang Instant patch for dermal drug delivery
US20060105028A1 (en) * 2004-11-12 2006-05-18 Jie Zhang Systems and methods for treating warts
US8080560B2 (en) * 2004-12-17 2011-12-20 3M Innovative Properties Company Immune response modifier formulations containing oleic acid and methods
JP2008526765A (ja) * 2004-12-30 2008-07-24 スリーエム イノベイティブ プロパティズ カンパニー 皮膚転移の処置
AU2006210392A1 (en) * 2005-02-04 2006-08-10 Coley Pharmaceutical Group, Inc. Aqueous gel formulations containing immune response modifiers
US20070049518A1 (en) * 2005-08-31 2007-03-01 Chandler Stephen R Novel method of treatment of inflammatory skin conditions
US8703753B2 (en) * 2005-09-15 2014-04-22 Biomas Ltd. Use of tellurium compounds for the treatment of actinic keratosis
US8889154B2 (en) * 2005-09-15 2014-11-18 Medicis Pharmaceutical Corporation Packaging for 1-(2-methylpropyl)-1H-imidazo[4,5-c] quinolin-4-amine-containing formulation
US20070081962A1 (en) 2005-10-06 2007-04-12 Amit Munshi Novel delivery of immune response modifiers for removal of chronic tattoos
GB0524962D0 (en) 2005-12-07 2006-01-18 Pharmakodex Ltd Topical pharmaceutical compositions
JP2009519958A (ja) 2005-12-14 2009-05-21 ザーズ， インコーポレイテッド 薬物の皮膚送達のための、フラックス化可能な組成物および方法
AU2006326033A1 (en) 2005-12-14 2007-06-21 Zars Pharma, Inc. Spray-on formulations and methods for dermal delivery of drugs
CN101378729B (zh) 2005-12-14 2013-09-11 扎尔斯制药公司 治疗皮肤症状的制剂和方法
US20070280972A1 (en) 2006-04-25 2007-12-06 Zars, Inc. Adhesive solid gel-forming formulations for dermal drug delivery
US20070264317A1 (en) 2006-05-15 2007-11-15 Perrigo Israel Pharmaceuticals Ltd. Imiquimod cream formulation
MX2009000507A (es) * 2006-07-14 2009-06-12 Stiefel Res Australia Pty Ltd Espuma farmaceutica de acidos grasos.
NO343857B1 (no) 2006-07-18 2019-06-24 Meda Ab Immunresponsmodifiserende skumformuleringer
CA2659733A1 (en) 2006-07-31 2008-02-07 3M Innovative Properties Company Sterilized topical compositions of 1-(2-methylpropyl)-1h-imidazo[4,5-c]quinolin-4-amine
PL2076260T3 (pl) * 2006-09-15 2011-08-31 Celgene Corp Związki N-metyloaminometylo-izoindolu, kompozycje zawierające te związki, oraz metody ich stosowania
PL2428513T3 (pl) * 2006-09-26 2017-10-31 Celgene Corp Pochodne 5-podstawionego chinazolinonu jako środki przeciwnowotworowe
WO2008052126A2 (en) * 2006-10-25 2008-05-02 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Ointment comprising phosphatidylserine as active agent for cancer treatment
FR2908289B1 (fr) * 2006-11-10 2009-01-23 Symatese Soc Par Actions Simpl Dispositif destine a la regeneration du derme et procede de fabrication dudit dispositif.
WO2008082381A1 (en) 2006-12-29 2008-07-10 3M Innovative Properties Company Immune response modifier formulations containing oleic acid and methods
EP2115140B8 (en) * 2007-01-31 2017-01-25 Chongxi Yu Positively charged water-soluble prodrugs of 1H-imidazo[4,5-c]quinolin-4-amines and related compounds with very high skin penetration rates
US20090018155A1 (en) * 2007-02-08 2009-01-15 Gregory Jefferson J Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy
WO2008118765A1 (en) 2007-03-23 2008-10-02 Graceway Pharmaceuticals, Llc Methods and packages to enhance safety when using imiquimod to treat children diagnosed with skin disorders
WO2008118763A1 (en) 2007-03-23 2008-10-02 Graceway Pharmaceuticals, Llc. Methods and packages to enhance safety when using imiquimod to treat children diagnosed with skin disorders
WO2008118881A1 (en) 2007-03-23 2008-10-02 Graceway Pharmaceuticals, Llc Method and packages to enhance safety when using imiquimod to treat children diagnosed with skin disorders
WO2008118762A1 (en) * 2007-03-23 2008-10-02 Graceway Pharmaceuticals, Llc Methods and packages to enhance safety when using imiquimod to treat children diagnosed with skin disorders
WO2008140713A1 (en) 2007-05-08 2008-11-20 The Brigham And Women's Hospital, Inc Methods and products for treating proliferative disorders
US8636982B2 (en) * 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
GB0715428D0 (en) 2007-08-08 2007-09-19 Imp Innovations Ltd Compositions and uses thereof
US20090130029A1 (en) * 2007-11-21 2009-05-21 Foamix Ltd. Glycerol ethers vehicle and pharmaceutical compositions thereof
WO2009069006A2 (en) * 2007-11-30 2009-06-04 Foamix Ltd. Foam containing benzoyl peroxide
BRPI0907191A2 (pt) 2008-01-15 2015-07-14 Dow Pharmaceutical Sciences Solução, método para preparar uma solução, método para aumentar a penetração cutânea de imiquimod ou um análogo do mesmo
MX2010008468A (es) 2008-01-31 2010-08-30 Curevac Gmbh Acidos nucleicos de la formula (i) (nug1xmgnnv)a y derivados de los mismos como un agente/adyuvante inmunoestimulante.
US20090246156A1 (en) * 2008-03-31 2009-10-01 Audrey Kunin Anti-acne sunscreen composition
CA2757437A1 (en) 2008-04-03 2009-12-03 Cognate 3, Llc Compositions and methods for immunotherapy
ES2498091T3 (es) * 2008-04-28 2014-09-24 Novartis Ag Procedimiento para producir nanopartículas
WO2009155070A2 (en) 2008-05-30 2009-12-23 Novelix Pharmaceuticals, Inc. Compositions and methods for treatment of inflammation and hyperkeratotic lesions
EP3650017A1 (en) 2008-06-26 2020-05-13 Anterios, Inc. Dermal delivery
US20100160368A1 (en) * 2008-08-18 2010-06-24 Gregory Jefferson J Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy
US8343498B2 (en) * 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US20110207765A1 (en) 2008-10-31 2011-08-25 Moberg Derma Ab Topical composition comprising a combination of at least two penetration enhancing agents
DK2378876T3 (en) * 2008-12-19 2019-03-11 Medicis Pharmaceutical Corp IMIQUIMOD FORMULATIONS WITH LOWER DOSAGE STRENGTH AND SHORT-TERM DOSAGE PLAN FOR TREATMENT OF ACTINIC KERATOSIS
WO2010088924A1 (en) 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
MX336923B (es) 2009-07-13 2016-02-05 Medicis Pharmaceutical Corp Formulaciones de imiquimod de concentracion de dosificacion inferior y regimenes de dosificacion cortos para tratar verrugas genitales y perianales.
US8476225B2 (en) * 2009-12-04 2013-07-02 Gilead Sciences, Inc. Antiviral compounds

Also Published As

Publication number Publication date
ZA201301397B (en) 2014-09-25
US8642616B2 (en) 2014-02-04
EP2453747A1 (en) 2012-05-23
PE20110064A1 (es) 2011-03-04
US20230020422A1 (en) 2023-01-19
AU2010274097A1 (en) 2013-10-10
WO2011008324A1 (en) 2011-01-20
CL2010000524A1 (es) 2011-04-01
US9078889B2 (en) 2015-07-14
TW201105668A (en) 2011-02-16
US11850245B2 (en) 2023-12-26
IL217518A0 (en) 2012-02-29
PL2453747T3 (pl) 2018-02-28
MX2011001410A (es) 2011-04-04
US20150328206A1 (en) 2015-11-19
US20120329824A1 (en) 2012-12-27
US20110207766A1 (en) 2011-08-25
EP2453747B1 (en) 2017-08-30
US10918635B2 (en) 2021-02-16
AR077747A1 (es) 2011-09-21
AU2010274097B2 (en) 2016-06-16
US20180271854A1 (en) 2018-09-27
BR112012000797A2 (pt) 2016-08-09
EA025993B1 (ru) 2017-02-28
US10238645B2 (en) 2019-03-26
US20120329825A1 (en) 2012-12-27
US20120289538A1 (en) 2012-11-15
US20190216796A1 (en) 2019-07-18
EP2453747A4 (en) 2012-12-05
ES2653313T3 (es) 2018-02-06
US20140187575A1 (en) 2014-07-03
CR20120068A (es) 2012-07-10
EA201290050A1 (ru) 2012-11-30
US20120329823A1 (en) 2012-12-27
GEP20156418B (en) 2016-01-11
MX336923B (es) 2016-02-05
US9980955B2 (en) 2018-05-29
TWI574689B (zh) 2017-03-21
UY32735A (es) 2011-02-28

Similar Documents

Publication Publication Date Title
DOP2012000007A (es) Formulaciones de imiquimod de concentracion de dosificacion inferior y regimenes de dosificacion cortos para tratar verrugas genitales y perianales
MX346455B (es) Formulaciones de imiquimod de baja concentracion de dosis y regimenes de dosis de corta duracion para tratar queratosis actinica.
MX2009008582A (es) Metodo para la administracion terapeutica de dihidroergotamina para permitir un rapido alivio de la migraña mientras se minimiza el perfil de efectos secundarios.
UA115139C2 (uk) Спосіб доставки фармацевтичної композиції, яка містить омепразол й ацетилсаліцилову кислоту, пацієнту
GB201104267D0 (en) Pyrrolopyridineamino derivatives
NZ605888A (en) Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of nociceptive pain
EA201490377A1 (ru) Лечение рассеянного склероза комбинацией лаквинимода и глатирамера ацетата
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
MX2021012272A (es) Metodos y composiciones para tratar el cancer e incrementar la inmunidad terapeutica reduciendo selectivamente los monocitos m2 inmunomoduladores.
WO2014160216A3 (en) Dual targeting anticancer agents
JOP20200031A1 (ar) طرق لعلاج الالتهاب العظمي المفصلي باستخدام هلام من كانابيديول عبر الأدمة
AR091724A1 (es) Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fampridina, composicion farmaceutica
MX348418B (es) Composicion ocular que contiene bromfenaco con biodisponibilidad incrementada.
MX2015009546A (es) Dosificacion aumentada de efavirenz para el tratamiento de cancer.
MX341660B (es) Agonista del receptor de ghrelina para el tratamiento de caquexia.
AR075866A1 (es) Una dosis de ave5026 para el tratamiento de tromboembolismo venoso en pacientes con deterioro renal severo. uso. composicion farmaceutica.
PH12014501601A1 (en) Artemisinin-based combination therapy for treating viral mediated disease
JOP20170044B1 (ar) تركيبة صيدلانية تشتمل على hgh ناتج عن عودة الارتباط الجيني لعلاج نقص هرمون النمو
BR112012020415A2 (pt) composição farmacêutica para a prevenção ou tratamento da osteoartrite
RU2012114097A (ru) Терапевтический агент против хронической боли
GT201200007A (es) Formulaciones de imiquimod de concentracion de dosificacion inferior y regimenes de dosificacion cortos para tratar verrugas genitales y perinales
TR201902178T4 (tr) Akti̇ni̇k keratozun tedavi̇si̇ne yöneli̇k düşük dozaj yi̇ti̇li̇ği̇ne sahi̇p i̇mi̇kui̇mod formülasyonlari ve kisa dozajli reji̇mler.
UY32375A (es) Formulaciones de imiquimod de baja concentración de dosis y regimenes de dosis de corta duración para tratar queratosis actínica
MX339367B (es) Composicion para tratar tuberculosis en base a perclorato de 4-tioureido-iminometilpiridinio: metodo de preparacion y tratamiento.
TNSN06305A1 (en) Treatment regimen for camptothecin derivatives